EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


facebook twitter youtube
News archive
Recent news

Myeloma Patients Europe has participating along with 13 European Patient organisations in the statement calling on European institutions to adopt appropriate measures to incorporate meaningful involvement of patients in EU cooperation on health technology assessment (HTA).

Patients and their organisations are convinced that changes need to be made to the legislation before it is adopted to guarantee an adequate involvement of patients in all HTA activities (joint consultations, early dialogues, scoping and assessments), which is essential to help HTA assessors determine the relative efficacy and safety of health technologies.

The joint statement contents four points explaining those aspects in which patient involvement can make a difference in the HTA process. Read the full document here.







Recent news

» Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosis

» Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlights

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.